Low-dose aspirin may not reduce CV events risk in diabeticsNovember 10th, 2008 - 12:50 pm ICT by ANI
Washington, Nov 10 (ANI): A new study, conducted by Japanese researchers, has revealed that low-dose aspirin as primary prevention does not appear to significantly reduce the risk of a combined end point of coronary, cerebrovascular and peripheral vascular events in patients with type 2 diabetes.
However, aspirin does significantly reduce the combination of fatal coronary and fatal cerebrovascular events.
“Diabetes mellitus is a powerful risk factor for cardiovascular events. Individuals with diabetes have a two- to four-fold increased risk of developing cardiovascular events than those without diabetes,” the researchers said.
For the study, Hisao Ogawa, M.D., Ph.D., from the Graduate School of Medical Sciences, Kumamoto University, Japan and colleagues, from the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators, examined whether low-dose aspirin would be beneficial for primary prevention of atherosclerotic (atherosclerosis, which involves narrowing or hardening of the arteries because of plaque build-up) events in patients with type 2 diabetes.
From Dec. 2002 through April 2008, 2,539 patients with type 2 diabetes and no history of atherosclerotic disease from 163 institutions from throughout Japan were enrolled in the study. Patients were randomly assigned to the low-dose aspirin group receiving 81 or 100 mg per day (n = 1,262) or the nonaspirin (n = 1,277) group.
The average age was 65 and 55 percent of the patients were men. The median (midpoint) follow-up period was 4.37 years. The main outcome measures were atherosclerotic events, including fatal or nonfatal ischemic heart disease, fatal or nonfatal stroke, and peripheral arterial disease.
“A total of 154 atherosclerotic events occurred: 68 in the aspirin group and 86 in the nonaspirin group. In the 1,363 patients aged 65 years or older (719 in the aspirin group and 644 in the nonaspirin group), the incidence of atherosclerotic events was significantly lower in the aspirin group (45 events, 6.3 percent) than in the nonaspirin group (59 events, 9.2 percent),” the researchers said.
In the 1,176 patients younger than 65 the difference among events in the two groups was not significant.
Aspirin was well tolerated: in comparing bleeding events, the researchers reported 13 hemorrhagic strokes, with no statistically significant difference
between aspirin takers and non-takers (six such strokes in the aspirin group; seven in the non-aspirin group).
There was a comparable number of the combined endpoint of serious hemorrhagic events (hemorrhagic strokes and major gastrointestinal bleeds).
While this study did not find that low-dose aspirin significantly reduced the risk of atherosclerotic events in primary prevention therapy in patients with type 2 diabetes, the authors suggest more research is needed.
The study will appear in the November 12 print issue of JAMA. (ANI)
- Aspirin may cut the risk of pancreatic cancer - Apr 05, 2011
- Aspirin cuts cancer risk - Mar 21, 2012
- Aspirin safer than warfarin in preventing stroke: Study - May 03, 2012
- Experts discourage younger diabetic patients from using Aspirin - Jun 02, 2010
- Dark chocolate reduces risk of cardiac fatalities - Jun 04, 2012
- Taking aspirin for heart disease prevention is less costly, more effective - Feb 23, 2011
- Aspirin reduces risk of cancer recurrence in prostate cancer patients - May 03, 2011
- Scientists warn against routinely using aspirin to prevent heart attacks, strokes - May 29, 2009
- 'Muscle cramp drug better than aspirin in preventing strokes' - Sep 12, 2010
- Insulin resistance may be linked to stroke risk - Oct 12, 2010
- Top 10 major advances in heart disease in 2010 - Dec 22, 2010
- Strokes hit smokers earlier than others - Oct 03, 2011
- High and low dose aspirin can protect heart - Mar 27, 2012
- An aspirin a day 'cuts cancer death rate by 50pc' - Dec 07, 2010
- Aspirin 'cuts stroke risk in patients with peripheral artery disease' - May 13, 2009
Tags: atherosclerotic events, cardiovascular events, cerebrovascular events, cv events, diabetes mellitus, hardening of the arteries, individuals with diabetes, ischemic heart disease, japanese researchers, kumamoto university, low dose aspirin, main outcome measures, nonfatal stroke, patients with type, peripheral arterial disease, primary prevention, risk factor, type 2 diabetes, university japan, vascular events